NASDAQ:BCLI
Brainstorm Cell Therapeutics Inc. Stock News
$0.535
+0.0025 (+0.470%)
At Close: Apr 26, 2024
BrainStorm Granted SME Status by the European Medicines Agency
01:00pm, Monday, 15'th Jun 2020
NEW YORK, June 15, 2020 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced.
Pat Quinn launches handlebar mustache challenge for ALS research
09:19pm, Friday, 12'th Jun 2020
The Mighty Pat Quinn is rallying people to raise money for ALS research through his #Handlebars4Hope challenge throughout the month of June.
BrainStorm to Present at the Raymond James Human Health Innovations Conference
11:28am, Thursday, 11'th Jun 2020
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Chaim Lebovits, CEO and Ralph Kern, MD, MHSc, Preside
BCLI: ALS Association and I AM ALS Awards $500,000 Grant; Potential Inclusion in Russell 3000 Index…
09:40am, Wednesday, 10'th Jun 2020
By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update $500,000 Grant from ALS Association and I AM ALS On June 9, 2020, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) an
The ALS Association, I AM ALS Award BrainStorm Cell Therapeutics $500,000 for ALS Biomarker Study
10:05am, Tuesday, 09'th Jun 2020The ALS Association, I AM ALS Award BrainStorm Cell Therapeutics $500,000 for ALS Biomarker Study
10:00am, Tuesday, 09'th Jun 2020
The ALS Association and I AM ALS announced today that the organizations have awarded a combined grant of $500,000 to BrainStorm Cell Therapeutics (NASDAQ: BCLI), a biotechnology company, to support an
Hedge Funds Warming Up To Brainstorm Cell Therapeutics Inc. (BCLI)
11:09pm, Thursday, 04'th Jun 2020
We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of Ma
BrainStorm to Participate in BIO Digital 2020
10:00am, Wednesday, 03'rd Jun 2020
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Dr. Ralph Kern, M.D, President and Chief Medical Offi
BrainStorm Announces That Pivotal Phase 3 Trial Remains On Track For Topline Data In Q4-2020
10:04am, Tuesday, 02'nd Jun 2020BrainStorm Announces that Pivotal Phase 3 Trial Remains on Track for Topline Data in Q4-2020
10:00am, Tuesday, 02'nd Jun 2020
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today an update on the Company's Phase 3 pivotal trial inve
Cancer-stricken boy's given a year to live, so best friend plans a 127-item bucket list
05:58pm, Monday, 01'st Jun 2020
Dillon Hill dropped out of college to help his terminally ill friend complete his bucket list. Now, he's continuing a mission of giving back.
65% Of Small Israeli Start-ups Could Succumb To COVID-19: Survey
04:57pm, Sunday, 31'st May 2020
65% of small Israeli start-ups could succumb to COVID-19: survey
Yogi Adityanath ropes in industry to provide 7.5 lakh jobs; UP moves to solve migrant labour woes
11:08am, Thursday, 28'th May 2020
With the unemployment crisis for migrant workers looming large, Chief Minister Yogi Adityanath has moved to address the labour woes by roping in industries to provide for as many as 7.5 lakh jobs in t
BrainStorm Appoints Pharmaceutical Veteran Stacy R. Lindborg, Ph.D. as Executive Vice President, Head of Global Clinical Research
11:25am, Wednesday, 27'th May 2020
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that Stacy R. Lindborg, Ph.D. has been appointed Exec
Virus slices into ALS dividends, but silver lining on horizon
04:29am, Wednesday, 27'th May 2020
The Brisbane-based testing giant also says some coal customers have backed its transparency in an analysis scandal.
